BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

...The anti-PD-1 mAb is the first approved immunotherapy in this setting regardless of PD-L1 expression. RIPK1...
...Denali, Sanofi Denali Therapeutics Inc. (NASDAQ:DNLI) and Sanofi (Euronext:SAN; NASDAQ:SNY) have paused clinical studies of RIPK1...
...death 1 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 BioCentury...
BioCentury | May 1, 2020
Distillery Therapeutics

Blocking necroptosis to treat inflammatory bowel disease

DISEASE CATEGORY: Autoimmune disease INDICATION: Inflammatory bowel disease (IBD) Inhibiting necroptosis by targeting RIPK3, MLKL or ZBP1 could treat IBD associated with deficiencies in the epigenetic protein SETDB1. Bowel tissue from IBD patients had lower...
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

...identified were Iclusig ponatinib from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), a lymphoma drug against RIPK1...
...containing 2 BRD4 - Bromodomain containing 4 PTGES2 - Prostaglandin E synthase-2 RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 Sandi...
BioCentury | Mar 16, 2020
Politics, Policy & Law

Biotech CEOs respond to Sanders attack: science, not politics, will defeat the pandemic

Biopharma executives rebuked Sen. Bernie Sanders (I-Vt.) for attacking them and the biopharmaceutical industry Sunday evening during a debate with former Vice President Joe Biden. Science, not politics, will defeat COVID-19, industry leaders told BioCentury....
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

...INDICATION: Stroke Preventing neuronal necroptosis by disrupting the interaction between ASIC1A, an acid-sensing ion channel, RIPK1...
...the interaction between ASIC1A’s C- and N-termini is disrupted, enabling the C terminus to activate RIPK1...
...ALS). TARGET/MARKER/PATHWAY: Acid-sensing ion channel-1A (ASIC1A); N-ethylmaleimide sensitive factor, vesicle fusing ATPase (NSF); receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1...
BioCentury | Feb 5, 2020
Product Development

Leaner GSK ups R&D investments in immunology, genetics

...in the failed NIAID study announced Monday. Of the eight pharma programs discontinued, three targeted RIPK1...
...was 123.9p, up 1%. Targets HIF-PH (EGLN) - Hypoxia-inducible factor prolyl hydroxylase RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1...
BioCentury | Nov 23, 2019
Politics, Policy & Law

Debating the fate of innovation

No one believes that H.R. 3, the Democratic House leadership’s drug pricing bill, will be enacted into law , but that hasn’t stopped it from precipitating frenzied debates. The bill has become a strawman for advocates...
BioCentury | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

...at least two compounds with DEL origins into the clinic and advanced one of them, RIPK1...
...tyrosine kinase Cbl-b - Casitas B cell lymphoma-b ENPP2 (ATX) - Autotaxin RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 Allison...
...Inc. Roche Pfizer Inc. The Scripps Research Institute University of California Irvine X-Chem Inc. Bruton's tyrosine kinase (Btk) Casitas B cell lymphoma-b (Cbl-b) Receptor-interacting serine-threonine kinase 1 (RIPK1) (RIP1) DNA-encoded...
BioCentury | Aug 26, 2019
Financial News

RIP Mark Schoenebaum, treasured biopharma analyst

Mark Schoenebaum, an admired biopharma equity analyst, died over the weekend. Schoenebaum resigned as senior managing director and head of healthcare/biotech & pharma equity analyst at Evercore ISI in 2017. Prior to joining Evercore in...
Items per page:
1 - 10 of 87